Restarting Wegovy after a 6-week break: what to consider

Why six weeks changes the restart calculation

A short gap of a week or two rarely changes the clinical picture much, and if your break was in that range, the guidance on restarting Wegovy after two weeks walks through what that shorter pause typically means for your dose. Six weeks is different. Semaglutide clears the body gradually (its half-life is roughly one week) so after six weeks, the medicine is effectively gone. With it goes the tolerance your digestive system built up during the original titration. The stomach emptying effects that caused nausea early in treatment can feel just as pronounced on a restart as they did the very first time.

This is why the NHS semaglutide patient guidance advises speaking to your prescriber rather than simply resuming at your previous dose. The guidance is not designed to be cautious for its own sake; it reflects what happens in practice when people jump back in at, say, 1.7 mg after several weeks off. Nausea, vomiting, and diarrhoea that felt manageable during the original ramp-up can return with real force.

One quick habit worth building before any restart: look at the expiry date printed on the pen. It takes under a minute, and an expired pen is one less complication to navigate mid-titration. Storage matters too, pens kept outside the fridge for longer than the Patient Information Leaflet permits should not be used.

If your gap was shorter, the guidance for restarting after roughly a month covers a slightly different dose-step calculation worth reading alongside this.

The step-back decision: where your prescriber is likely to land

There is no single universal rule that overrides clinical judgement here, but the general principle is consistent: the longer the break and the higher the dose you had reached, the more conservative the restart. Someone who had been stable on 2.4 mg for several months will almost certainly be advised to return to 1.0 mg or 1.7 mg rather than picking up at their previous maintenance dose. Someone who had only just reached 1.0 mg before the break might restart at 0.5 mg.

The specific restart point depends on what you and your prescriber discuss, your current weight, any symptoms you noticed during the break, and whether anything in your health has changed. This is not a box-ticking exercise. A prescriber on the Wegovy treatment pathway at a regulated service reviews the full picture before making a recommendation, including any evidence you can provide about where you were in your dose schedule before stopping.

People who stopped because of side effects need to be especially open about that when they restart. If nausea or vomiting was the reason you paused, restarting at a lower dose and titrating more slowly (spending longer at each step than the standard four-week schedule) is a reasonable approach your prescriber may suggest. Pushing through at the dose that caused problems is unlikely to end differently the second time.

Weight regain during the gap is worth raising honestly too. It is not a cause for embarrassment; the biology of semaglutide means appetite regulation fades when the medicine stops, and regain is an expected pharmacological consequence rather than a failure of willpower.

What changes after a longer break, and when to consider starting fresh

Six weeks sits at the boundary between a pause and a longer interruption. For context, if your break were closer to six months, the clinical approach shifts again, at that point, most prescribers treat it effectively as a new course of treatment, starting from 0.25 mg and titrating from scratch. Restarting after six months off Wegovy covers that scenario separately.

At six weeks, you are in an intermediate zone. You may not need to go all the way back to 0.25 mg, but you will likely need to step back at least one or two rungs. The right answer is individual. What a prescriber is doing, when they suggest a lower restart dose, is giving your system the same courtesy the titration schedule gave it originally: time to readjust.

It is also worth thinking about why the break happened and whether anything has changed. If your gap landed closer to three weeks, the specific considerations for restarting Wegovy after three weeks may also be useful to read before your clinical review. The former often resolves with a careful restart; the latter might warrant a broader conversation about whether Wegovy is the right fit or whether the titration pace needs adjusting. Our clinical team takes both situations seriously.

Getting a clinical review before you restart

Restarting a prescription medicine after a significant gap is not something to do without clinical input. Whether your original prescription came from a GP, a specialist service, or a private provider like a regulated online clinic, a prescriber needs to reassess before you resume. At nume, every repeat order goes through a fresh clinical review, not a formality, but a genuine check that the restart plan is appropriate for where you are now.

That review is also the right moment to flag anything that has changed: new medications, a change in your weight or health conditions, or any side effects that prompted the break. The NHS patient guidance on semaglutide is clear that dose adjustments should be made in consultation with your healthcare provider, not independently. That advice applies just as much to restarts as it does to the original titration.

If you are considering resuming Wegovy and want a prescriber to review your situation, starting with a free consultation is the logical first step. There is no pressure toward a particular outcome, the review exists to make sure whatever comes next is clinically right for you.